New credential for co-occurring disorders will pressure addiction professionals

Alcoholism & Drug Abuse Weekly exclusively reports in their April 23 issue, that a new credential, represented by the initials CCDP (Certified Co-Occurring Disorders Professional) was introduced last week by the International Certification & Reciprocity Consortium/Alcohol and Other Drug Abuse (IC&RC) in a move that pressures the addiction treatment workforce to get more training, according to a report.

This new certification is meant to treat patients with both mental and substance use, or co-occurring disorders. These patients have historically been given conflicting advice or been told to get one treatment first over the other. The new credential will make it possible for addiction professionals to show they have the ability to treat co-occurring disorders.

In the brewing controversy about who will treat people with co-occurring substance use and mental health disorders , addiction or mental health professionals , turf, jobs, and millions of funding dollars are at stake. Not all addicts have co-occurring mental disorders, but as many as 80 percent do. Those people need specialized treatment that integrates best practices for treating both disorders at the same time, according to experts in the field. If people with co-occurring disorders are shuttled from program to program, neither condition will be treated successfully, studies have shown.

The new credential paves the way for a change in the treatment system, which has always had federal and state-level systemic barriers to integration of addiction and mental health treatment, according to Dalphonse. "The practitioner who will survive is the one who can deal with the interactive relationship of these two disorders," he said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 receptor agonists show promise in treating substance use disorders